SREBP-2, a new target of metformin?

BACKGROUND: Metformin, as the first-line treatment anti-diabetic drug, represents increasing evidence of a potential efficacy in improving dyslipidemia. However, the exact molecular mechanism(s) by which metformin influences lipid metabolism remains incompletely understood. METHODS: The HepG2 cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fengxia, Sun, Wenxiu, Chen, Jianbo, Jiang, Lusheng, Yang, Ping, Huang, Yufang, Gong, Aihua, Liu, Shudong, Ma, Shizhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287532/
https://www.ncbi.nlm.nih.gov/pubmed/30584280
http://dx.doi.org/10.2147/DDDT.S190094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287532/
https://www.ncbi.nlm.nih.gov/pubmed/30584280
http://dx.doi.org/10.2147/DDDT.S190094

Ejemplares similares